Travere Therapeutics (TVTX) Interest Coverage Ratio (2011 - 2026)
Travere Therapeutics (TVTX) posted Interest Coverage Ratio of 16.05 for Q1 2026, down 11.26% on a QoQ basis from 14.43 in Q4 2025, and down 9.07% year-over-year from 17.65 in Q1 2025.
Travere Therapeutics (TVTX) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Travere Therapeutics' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 16.05 for Q1 2026.
- Quarterly Interest Coverage Ratio fell 9.07% year-over-year to 16.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.59 (up 78.03% YoY) and the FY2025 annual result came in at 0.17, up 81.98% from the prior year.
- Interest Coverage Ratio was 16.05 for Q1 2026 at Travere Therapeutics, down from 14.43 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 9.06 in Q3 2025 and bottomed at 138.67 in Q4 2024.
- A 5-year average of 30.7 and a median of 28.79 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio slumped 427.44% — and 2025, when it surged 145.19%.
- Travere Therapeutics' Interest Coverage Ratio stood at 30.81 in 2022, then declined by 9.23% to 33.65 in 2023, then tumbled by 312.04% to 138.67 in 2024, then surged by 89.6% to 14.43 in 2025, then fell by 11.26% to 16.05 in 2026.
- Business Quant data shows TVTX's Interest Coverage Ratio at 16.05 in Q1 2026, 14.43 in Q4 2025, and 9.06 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -16.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.05 |
| Dec 31, 2025 | -14.43 |
| Sep 30, 2025 | 9.06 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -14.72 |
| Dec 31, 2024 | -138.67 |
| Sep 30, 2024 | -20.05 |
| Jun 30, 2024 | -24.28 |
| Mar 31, 2024 | -49.73 |
| Dec 31, 2023 | -33.65 |
| Sep 30, 2023 | -32.82 |
| Jun 30, 2023 | -37.13 |
| Mar 31, 2023 | -33.58 |
| Dec 31, 2022 | -30.81 |
| Sep 30, 2022 | -29.50 |
| Jun 30, 2022 | -26.18 |
| Mar 31, 2022 | -28.79 |
| Dec 31, 2021 | -5.84 |
| Sep 30, 2021 | -18.38 |
| Jun 30, 2021 | -7.83 |